MERRIMACK PHARMACEUTICALS IN (MACK) Stock Price, Quote, News and Overview
NASDAQ:MACK - Nasdaq - US5903282094 - Common Stock - Currency: USD
MACK Quote, Performance and Key Statistics
15.13
0 (0%)
The current stock price of MACK is 15.13 USD. In the past month the price increased by 2.79%. In the past year, price increased by 18.95%.
MACK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.17 | 360.64B | ||
| AMGN | AMGEN INC | 15.63 | 166.32B | ||
| GILD | GILEAD SCIENCES INC | 24.08 | 138.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1660.86 | 123.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.63 | 77.97B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.11B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.04B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.58B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.58 | 20.59B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B |
Related stock screener links
About MACK
Company Profile
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2012-03-29. The firm does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The firm is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Company Info
MERRIMACK PHARMACEUTICALS IN
One Broadway, 14th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Gary L. Crocker
Employees: 0
Company Website: https://www.merrimack.com/
Phone: 16174411000
MERRIMACK PHARMACEUTICALS IN / MACK FAQ
What is the stock price of MERRIMACK PHARMACEUTICALS IN today?
The current stock price of MACK is 15.13 USD.
What is the ticker symbol for MERRIMACK PHARMACEUTICALS IN stock?
The exchange symbol of MERRIMACK PHARMACEUTICALS IN is MACK and it is listed on the Nasdaq exchange.
On which exchange is MACK stock listed?
MACK stock is listed on the Nasdaq exchange.
What is MERRIMACK PHARMACEUTICALS IN worth?
MERRIMACK PHARMACEUTICALS IN (MACK) has a market capitalization of 223.77M USD. This makes MACK a Micro Cap stock.
How many employees does MERRIMACK PHARMACEUTICALS IN have?
MERRIMACK PHARMACEUTICALS IN (MACK) currently has 0 employees.
What are the support and resistance levels for MERRIMACK PHARMACEUTICALS IN (MACK) stock?
MERRIMACK PHARMACEUTICALS IN (MACK) has a support level at 15.09 and a resistance level at 15.14. Check the full technical report for a detailed analysis of MACK support and resistance levels.
Should I buy MERRIMACK PHARMACEUTICALS IN (MACK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MACK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MACK, evaluating the profitability, health, valuation and growth aspects
- MERRIMACK PHARMACEUTICALS IN (MACK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MERRIMACK PHARMACEUTICALS IN (MACK) Sales and EPS estimates to see what analysts future expectations are.
- MERRIMACK PHARMACEUTICALS IN (MACK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MERRIMACK PHARMACEUTICALS IN (MACK) Insider and Institutional Ownership to learn about the owners and their transactions.
- MERRIMACK PHARMACEUTICALS IN (MACK) Stock Chart to make your own analysis
- MERRIMACK PHARMACEUTICALS IN (MACK) Latest news and press-releases to stay up to date.
Does MERRIMACK PHARMACEUTICALS IN (MACK) stock pay dividends?
MERRIMACK PHARMACEUTICALS IN (MACK) has a dividend yield of 99.8%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of MACK dividend history, reliability and sustainability.
When does MERRIMACK PHARMACEUTICALS IN (MACK) report earnings?
MERRIMACK PHARMACEUTICALS IN (MACK) will report earnings on 2024-08-01, after the market close.
What is the Price/Earnings (PE) ratio of MERRIMACK PHARMACEUTICALS IN (MACK)?
The PE ratio for MERRIMACK PHARMACEUTICALS IN (MACK) is 1.09. This is based on the reported non-GAAP earnings per share of 13.86 and the current share price of 15.13 USD. Check the full fundamental report for a full analysis of the valuation metrics for MACK.
MACK Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MACK. When comparing the yearly performance of all stocks, MACK turns out to be only a medium performer in the overall market: it outperformed 66.97% of all stocks.
MACK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MACK. MACK has a great financial health rating, but its profitability evaluates not so good.
MACK Financial Highlights
Over the last trailing twelve months MACK reported a non-GAAP Earnings per Share(EPS) of 13.86. The EPS increased by 10764.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 82.05% | ||
| ROE | 90.44% | ||
| Debt/Equity | 0 |
MACK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 45% to MACK. The Buy consensus is the average rating of analysts ratings from 8 analysts.